Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Adult Gliosarcoma
- Glioblastoma
- Neoplasms, Brain
- Neoplasms, Germ Cell and Embryonal
- Recurrent Glioblastoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 19 years and 70 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04657315
- Collaborators
- Ajou University School of Medicine
- Investigators
- Principal Investigator: Kyunggi Cho, MD,PhD CHA University
Get Well Soon